BBS2 — Bardet-Biedl syndrome 2

The BBS2 gene provides instructions for making a protein that is a crucial part of a structure called the BBSome. The BBSome acts like a cellular delivery service, specifically working within tiny, hair-like projections on the surface of cells called cilia. In the eyes, these cilia are essential for the light-sensing cells (photoreceptors) to function properly. The BBSome helps transport important proteins to where they need to be so the eye can detect light and send signals to the brain. It also plays similar roles in cilia found in the kidneys, brain, and other organs. When the BBS2 gene is mutated, the BBSome cannot form or work correctly. In the eyes, this means that essential proteins get stuck in the wrong parts of the photoreceptor cells, eventually causing these cells to die. This leads to a condition called Bardet-Biedl syndrome (BBS). For patients, this typically starts as night blindness in childhood and progresses to a severe loss of peripheral and central vision over time. Because cilia are important throughout the body, patients may also experience weight gain (obesity), extra fingers or toes, kidney problems, and learning difficulties. BBS2-related Bardet-Biedl syndrome is inherited in an autosomal recessive pattern. This means that a person must inherit two mutated copies of the gene—one from each parent—to develop the condition. The parents, who each carry one mutated copy, usually do not show any symptoms of the disease. If both parents are carriers, there is a 25% chance with each pregnancy of having a child affected by the syndrome. Genetic testing can help confirm the diagnosis and guide family planning.

Gene description: BBS2 encodes a BBSome component, critical for cilia structure and function, whose mutations cause Bardet-Biedl syndrome.

Patient and family guide: The BBS2 gene provides instructions for making a protein that is a crucial part of a structure called the BBSome. The BBSome acts like a cellular delivery service, specifically working within tiny, hair-like projections on the surface of cells called cilia. In the eyes, these cilia are essential for the light-sensing cells (photoreceptors) to function properly. The BBSome helps transport important proteins to where they need to be so the eye can detect light and send signals to the brain. It also plays similar roles in cilia found in the kidneys, brain, and other organs. When the BBS2 gene is mutated, the BBSome cannot form or work correctly. In the eyes, this means that essential proteins get stuck in the wrong parts of the photoreceptor cells, eventually causing these cells to die. This leads to a condition called Bardet-Biedl syndrome (BBS). For patients, this typically starts as night blindness in childhood and progresses to a severe loss of peripheral and central vision over time. Because cilia are important throughout the body, patients may also experience weight gain (obesity), extra fingers or toes, kidney problems, and learning difficulties. BBS2-related Bardet-Biedl syndrome is inherited in an autosomal recessive pattern. This means that a person must inherit two mutated copies of the gene—one from each parent—to develop the condition. The parents, who each carry one mutated copy, usually do not show any symptoms of the disease. If both parents are carriers, there is a 25% chance with each pregnancy of having a child affected by the syndrome. Genetic testing can help confirm the diagnosis and guide family planning.

Gene function: BBS2 is vital for maintaining retinal health by contributing to the integrity and function of cilia in photoreceptor cells. It is involved in intraflagellar transport (IFT), a process that moves proteins along the cilium, essential for the development and maintenance of the light-sensing outer segments. Defects in BBS2 lead to photoreceptor degeneration and progressive vision impairment.

Protein structure: The BBS2 gene encodes the Bardet-Biedl syndrome 2 protein, which in humans consists of 721 amino acids. Structurally, BBS2 contains domains that facilitate protein-protein interactions, which are essential for its role in the BBSome complex. It possesses a beta-propeller domain and interacts with other BBS proteins, notably binding to BBS7 via its C-terminus and to MKKS (BBS6) via a coiled-coil domain. BBS2 does not function in isolation; it co-assembles with seven other BBS proteins (BBS1, BBS4, BBS5, BBS7, BBS8, BBS9, and BBIP10) to form the stable, hetero-octameric BBSome core complex. The structural integrity of BBS2 is vital for the overall stability and assembly of the BBSome. Mutations that alter the amino acid sequence of BBS2 often disrupt these critical protein-protein interactions, preventing the proper formation of the BBSome and leading to defective ciliary transport.

Molecular function: The BBS2 gene encodes a core component of the BBSome, a highly conserved, octameric protein complex (composed of BBS1, BBS2, BBS4, BBS5, BBS7, BBS8, BBS9, and BBIP10) that is essential for the normal function of primary cilia. The BBSome functions as a coat complex that mediates the sorting and trafficking of specific membrane proteins to and from the primary cilium. It is required for ciliogenesis and the maintenance of ciliary structure, acting in concert with the intraflagellar transport (IFT) machinery. In photoreceptors, which possess a specialized sensory cilium (the connecting cilium), the BBSome is critical for the transport of phototransduction proteins, such as rhodopsin, from the inner segment to the outer segment. Loss of BBS2 function disrupts the BBSome assembly or function, leading to the mislocalization and ectopic accumulation of these proteins in the inner segment and cell body. This intracellular trafficking defect causes cellular stress, inadequate homeostasis, and ultimately the apoptotic death of photoreceptor cells. The BBSome also interacts with the Rab8 GTPase to promote ciliary membrane biogenesis and regulates signaling pathways, including the Sonic Hedgehog (SHH) pathway, which is vital for development.

Expression pattern: The BBS2 gene is widely expressed across multiple tissues, consistent with its role in the ubiquitous primary cilium. In the eye, BBS2 is highly expressed in the retina, specifically localizing to the connecting cilium, inner segment, and basal body of both rod and cone photoreceptors. It is also expressed in the retinal pigment epithelium (RPE), where primary cilia are critical for development and maturation. Beyond the eye, BBS2 expression is found in the ciliated cells of the inner ear (including cochlear hair cells), the olfactory epithelium, the brain, kidneys, and gonads. The widespread expression pattern correlates with the multi-organ phenotype observed in Bardet-Biedl syndrome, affecting sensory perception, renal function, and metabolic regulation.

Mutation spectrum: The mutation spectrum of the BBS2 gene includes a wide variety of pathogenic variants, such as missense, nonsense, frameshift, and splice-site mutations, as well as larger deletions. BBS2 mutations account for approximately 8-10% of all Bardet-Biedl syndrome cases. Over 100 pathogenic variants have been identified and cataloged in databases like ClinVar. While mutations are distributed throughout the gene, certain populations exhibit founder mutations. Notably, a specific founder mutation in BBS2 (c.534+1G>T) is responsible for a high prevalence of Bardet-Biedl syndrome in the Hutterite population of North America. In the Ashkenazi Jewish population, two specific mutations (c.311A>C and c.1895G>C) have been identified with established carrier frequencies. The wide variety of mutation types contributes to the phenotypic variability seen in patients.

Pathogenic variants: 1. c.534+1G>T - A well-characterized splice-site founder mutation highly prevalent in the Hutterite population, causing classic syndromic BBS. 2. p.Val75Gly (c.224T>G) - A missense variant frequently reported in ClinVar, associated with Bardet-Biedl syndrome and sometimes exhibiting variable expressivity. 3. p.Tyr24* (c.72C>G) - A nonsense mutation leading to premature protein truncation, resulting in a loss of function and severe BBS phenotype. 4. p.Arg275* (c.823C>T) - Another nonsense mutation that disrupts the BBSome complex formation, causing classic BBS features including early-onset retinal dystrophy. 5. p.Asp104Ala (c.311A>C) - A missense mutation with a known carrier frequency in the Ashkenazi Jewish population, contributing to the BBS phenotype when inherited in trans with another pathogenic allele.

Clinical significance: Mutations in the BBS2 gene cause Bardet-Biedl syndrome 2 (BBS2), an autosomal recessive ciliopathy. The clinical manifestations are highly pleiotropic and typically include early-onset severe rod-cone dystrophy (retinitis pigmentosa), truncal obesity, postaxial polydactyly, cognitive impairment, hypogonadism, and renal anomalies. Retinal degeneration is the most penetrant feature, often presenting as night blindness in the first decade of life, followed by progressive loss of peripheral vision, color vision, and visual acuity, frequently leading to legal blindness by the second or third decade. Renal disease is a major cause of morbidity and mortality in BBS patients, ranging from structural anomalies to progressive chronic kidney disease. Other systemic features can include developmental delay, speech deficits, diabetes mellitus, cardiovascular anomalies, and anosmia. The severity of the phenotype can vary significantly even among individuals with the same mutations, and some BBS2 mutations have been associated with non-syndromic retinitis pigmentosa without the full spectrum of BBS features.

Inheritance: Autosomal Recessive

Chromosomal location: 16q13

Genotype-phenotype correlations: Genotype-phenotype correlations in BBS2 are complex and highly variable. While null mutations (such as nonsense or frameshift variants) typically result in the classic, severe multi-systemic Bardet-Biedl syndrome phenotype, certain missense mutations have been linked to milder or atypical presentations. For instance, specific missense variants in BBS2 have been reported to cause non-syndromic retinitis pigmentosa (RP74), where patients experience retinal degeneration without the obesity, polydactyly, or cognitive issues typical of BBS. Additionally, the genetic background can influence the phenotype. BBS was initially proposed to sometimes exhibit triallelic inheritance, where a homozygous mutation in one BBS gene (e.g., BBS2) combined with a heterozygous mutation in another BBS gene (e.g., BBS6) exacerbates the phenotype. However, the majority of BBS2 cases follow classic autosomal recessive inheritance. The presence of modifier genes and the specific nature of the BBS2 variant both play significant roles in determining the onset, severity, and specific organ involvement in affected individuals.

Research and therapeutic approaches: Currently, there is no cure for the retinal degeneration or the underlying genetic defect in BBS2-related Bardet-Biedl syndrome. Management is primarily supportive and multidisciplinary, focusing on treating the systemic manifestations. For the visual impairment, patients are provided with low-vision aids and mobility training. A significant recent advancement in the systemic treatment of BBS is the FDA approval of Setmelanotide (Imcivree), a melanocortin-4 receptor (MC4R) agonist. Setmelanotide is approved for chronic weight management in patients 6 years and older with BBS, addressing the severe hyperphagia and early-onset obesity caused by hypothalamic dysfunction in these patients. In terms of pipeline therapies targeting the retinal dystrophy, gene therapy is an active area of preclinical research. Studies in Bbs2-null mouse models have demonstrated that subretinal injection of adeno-associated virus (AAV) vectors carrying the wild-type Bbs2 gene can rescue BBSome localization, reduce protein mislocalization, and preserve photoreceptor function and survival. While AAV-based gene therapies for other IRDs (like Luxturna for RPE65) are approved, BBS2 gene therapy has not yet entered human clinical trials. Other investigational approaches, such as antisense oligonucleotides (ASOs) and read-through therapies for nonsense mutations, are also being explored for ciliopathies, though they remain in the early stages of development for BBS2.

Diagnostic testing: Diagnosis of BBS2-related Bardet-Biedl syndrome is typically confirmed through molecular genetic testing. Given the high genetic heterogeneity of BBS (with over 20 genes implicated), testing is usually performed using a multigene panel that includes BBS2 and other ciliopathy genes, or through comprehensive genomic testing such as whole exome sequencing (WES) or whole genome sequencing (WGS). These methods can detect missense, nonsense, and splice-site variants, as well as small deletions or insertions. Copy number variant (CNV) analysis may also be included to detect larger deletions or duplications. Genetic counseling is essential for affected individuals and their families. Since BBS2 is inherited in an autosomal recessive manner, parents of an affected child are obligate carriers (heterozygotes) and have a 25% chance of having another affected child in each subsequent pregnancy. Carrier testing for at-risk relatives and prenatal testing for pregnancies at increased risk are possible if the pathogenic variants in the family are known. Electroretinography (ERG) is also used clinically to detect early signs of retinal dysfunction before significant fundus changes are visible.

Animal models: The primary animal models used to study BBS2 are Bbs2-null (knockout) mice and zebrafish models. Bbs2-null mice exhibit major components of the human Bardet-Biedl syndrome phenotype, including obesity, retinopathy, and olfactory deficits. In these mice, retinal development is initially normal, but it is followed by apoptotic death of photoreceptors, which are the primary ciliated cells of the retina. The outer segments of photoreceptors become disorganized, and there is an abnormal accumulation of proteins, indicating defective intraflagellar transport. Zebrafish bbs2 mutants are also utilized, particularly to study ciliary function, retinal degeneration, and neuroinflammation, revealing that cone degeneration leads to an inflammatory response and that BBS2 is necessary for cone survival.

Population genetics: The prevalence of Bardet-Biedl syndrome varies globally, ranging from 1 in 160,000 in Northern European populations to much higher rates in isolated or consanguineous communities. BBS2 mutations account for roughly 8-10% of these cases. Specific founder effects have been documented; for example, a BBS2 founder mutation (c.534+1G>T) is the primary cause of BBS in the Hutterite population of North America. In the Ashkenazi Jewish population, carrier screening has identified specific BBS2 mutations (such as c.311A>C and c.1895G>C) with a combined carrier frequency of approximately 1 in 136. In the general population, pathogenic alleles in BBS2 are rare, as reflected by low allele frequencies in large genomic databases like gnomAD.

Selected references: 1. Nishimura DY, et al. Positional cloning of a novel gene on chromosome 16q causing Bardet-Biedl syndrome (BBS2). Hum Mol Genet, 2001. PMID: 11285252 2. Nachury MV, et al. A core complex of BBS proteins cooperates with the GTPase Rab8 to promote ciliary membrane biogenesis. Cell, 2007. PMID: 17574030 3. Innes AM, et al. A founder mutation in BBS2 is responsible for Bardet-Biedl syndrome in the Hutterite population: utility of SNP arrays in genetically heterogeneous disorders. Clin Genet, 2010. PMID: 20618352 4. Nishimura DY, et al. Bbs2-null mice have neurosensory deficits, a defect in social dominance, and retinopathy associated with mislocalization of rhodopsin. Proc Natl Acad Sci U S A, 2004. PMID: 15534205 5. Forsythe E, Beales PL. Bardet-Biedl syndrome. Eur J Hum Genet, 2013. PMID: 22713813 6. Shevach E, et al. Association between missense mutations in the BBS2 gene and nonsyndromic retinitis pigmentosa. JAMA Ophthalmol, 2015. PMID: 25541840 7. Haws RM, et al. Clinical Practice Recommendations for the Diagnosis and Management of Bardet-Biedl Syndrome. Front Pediatr, 2018. PMID: 29552554